A phase 2 trial of 5-imino-13-deoxydoxorubicin (GPX-150) in metastatic and non-resectable soft tissue sarcomas

Abstract

Peer reviewed

Brian Andrew Van Tine, Mark Agulnik, Richard D. Olson, Gerald M. Walsh, Arthur Klausner and Mohammed M. Milhem

Journal of clinical oncology, Vol.34(15_suppl), pp.11019-11019

05/20/2016

DOI: 10.1200/JCO.2016.34.15_suppl.11019

View Online

Title: Subtitle: A phase 2 trial of 5-imino-13-deoxydoxorubicin (GPX-150) in metastatic and non-resectable soft tissue sarcomas
Creators: Brian Andrew Van Tine - Washington University in St. Louis
Mark Agulnik - Northwestern University
Richard D. Olson - Gem Pharmaceuticals
Gerald M. Walsh - Gem Pharmaceuticals
Arthur Klausner - Gem Pharmaceuticals
Mohammed M. Milhem - University of Iowa
Resource Type: Abstract
Publication Details: Journal of clinical oncology, Vol.34(15_suppl), pp.11019-11019
DOI: 10.1200/JCO.2016.34.15_suppl.11019
ISSN: 0732-183X
eISSN: 1527-7755
Language: English
Date published: 05/20/2016
Academic Unit: Internal Medicine; Hematology, Oncology, and Blood & Marrow Transplantation
Record Identifier: 9984363306302771

2 Record Views